Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Mendarion Aktie 41380740 / DE000A2LQ2D0

10.11.2025 16:30:44

EQS-News: 029 Group SE: Portfolio company TRIP closes $40m funding round

EQS-News: 029 Group SE / Key word(s): Investment
029 Group SE: Portfolio company TRIP closes $40m funding round

10.11.2025 / 16:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 10th November 2025. 029 Group SE (ISIN: DE000A2LQ2D0), a global hospitality and lifestyle platform, proudly announces proudly announces that its portfolio company TRIP has successfully closed a $40 million funding round at a significantly higher valuation.

Founded in London and led by CEO and cofounder Olivia Ferdi, TRIP has become one of the fastest-growing wellness brands globally, championing a new category of “calming beverages.” The company projects $100 million in profitable revenue for 2025, with expectations to double that by 2026, signaling robust growth in the booming functional drinks sector.

The $40 million funding will accelerate TRIP’s U.S. expansion and strengthen its partnership with Calm, the leading meditation app with over 100m downloads. With a diversified product range spanning magnesium drinks, supplement gummies, and electrolytes, TRIP is evolving into a global wellness powerhouse, already available in 10,000 U.S. locations and 50,000 worldwide through major retailers such as Target, Whole Foods, and CVS.

TRIP’s rapid growth has been fueled by strong community engagement and celebrity backers such as Joe Jonas, Alessandra Ambrosio, Paul Wesley, and Ashley Graham, alongside growth-stage investor Coefficient Capital. Over the past year alone, TRIP has generated over half a billion social media impressions, reflecting its resonance with consumers seeking healthier, stress-reducing alternatives to alcohol and sugary sodas.

“Leading this category of calming beverages meant we couldn’t rely on a blueprint,” said Olivia Ferdi, Co-Founder and CEO of TRIP. “Being highly customer-centric and building a community around a shared mission is what drives sustainable growth.”

Leon Sander, Managing Director of 029 Group SE, commented: “We’ve backed TRIP from day one and have been impressed by its exceptional execution, strong brand momentum, and disciplined global expansion. In the functional beverage market where prebiotic pioneers like Poppi, acquired by PepsiCo for 1.95 billion dollars, and OLIPOP, valued at 1.85 billion dollars, have established strong positions, TRIP is redefining a distinct and rapidly growing category.“

 

About TRIP Ltd.
TRIP is a UK-based consumer brand on a mission to help you find your calm amidst the chaos. Thanks to TRIP’s commitment to using only the highest quality CBD available in the UK, the range of delicious CBD infused drinks and oils are loved by their customers and has cemented TRIP’s position as a leading premium CBD brand.

Further information: https://drink-trip.com/

 

About 029 Group SE
029 Group SE believes that the next generation of consumer brands will be built on connection, experiences, and community. In a post-pandemic world, new patterns of work, life and leisure are emerging and accelerating. These trends create opportunities in hospitality and lifestyle for innovation-driven entrepreneurship with a strong community focus. 029 Group backs the most audacious entrepreneurs with a hands-on investment approach, focusing on areas where they can add significant value through their platform, global network and company building expertise. 029 Group is based in Berlin, Germany.

Further Information: https://www.029-group.com/

 

029 Group SE
Kurfürstendamm 14
10719 Berlin
E-Mail: ir@029-group.com
https://www.029-group.com/



10.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: 029 Group SE
Kurfürstendamm 14
10179 Berlin
Germany
E-mail: ir@029-group.com
Internet: www.029-group.com
ISIN: DE000A2LQ2D0
WKN: A2LQ2D
Listed: Regulated Market in Dusseldorf, Munich
EQS News ID: 2227138

 
End of News EQS News Service

2227138  10.11.2025 CET/CEST

Analysen zu Mendarion SE Inhaber-Akt

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’974.31 19.37 BP9SUU
Short 13’215.46 13.98 BU9S6U
Short 13’724.19 8.85 B19SNU
SMI-Kurs: 12’465.39 10.11.2025 17:30:00
Long 11’962.62 19.84 SNLBQU
Long 11’690.01 13.82 SSTBSU
Long 11’209.46 8.98 SQZB6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com